Minimally Invasive Treatment Options for Hepatic Uveal Melanoma Metastases

Sajan, Abin; Fordyce, Samuel B.; Sideris, Andrew; Liou, Connie; Toor, Zeeshan; Filtes, John; Krishnasamy, Venkatesh; Ahmad, Noor Ani; Reis, Stephen P.; Brejt, S.; Baig, Asad; Khan, Shaheer; Caplan, Michael S.; Sperling, David; Weintraub, Joshua

doi:10.3390/diagnostics13111836

Cited by 3 publications

(1 citation statement)

References 69 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, surgery is not always feasible, especially if the metastases are widespread or if the patient's overall health is compromised [45]. Other liver-directed therapies are hepatic artery infusion (HAI) [46] and transarterial chemoembolization (TACE) [47]. The efficiency of chemotherapy using cytotoxic agents in liver metastatic lesions is insignificant [31,43].…”

Section: Current Therapy Of Ummentioning

confidence: 99%

From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma

Synoradzki,

Paduszyńska,

Solnik

et al. 2024

Current Oncology

View full text Add to dashboard Cite

Molecular biology studies of uveal melanoma have resulted in the development of novel immunotherapy approaches including tebentafusp—a T cell–redirecting bispecific fusion protein. More biomarkers are currently being studied. As a result, combined immunotherapy is being developed as well as immunotherapy with bifunctional checkpoint inhibitory T cell engagers and natural killer cells. Current trials cover tumor-infiltrating lymphocytes (TIL), vaccination with IKKb-matured dendritic cells, or autologous dendritic cells loaded with autologous tumor RNA. Another potential approach to treat UM could be based on T cell receptor engineering rather than antibody modification. Immune-mobilizing monoclonal T cell receptors (TCR) against cancer, called ImmTAC TM molecules, represent such an approach. Moreover, nanomedicine, especially miRNA approaches, are promising for future trials. Finally, theranostic radiopharmaceuticals enabling diagnosis and therapy with the same molecule bring hope to this research.

show abstract

Section: Current Therapy Of Ummentioning

confidence: 99%

From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma

Synoradzki,

Paduszyńska,

Solnik

et al. 2024

Current Oncology

View full text Add to dashboard Cite

show abstract

Programmed Cell Death-Related Gene Signature Associated with Prognosis and Immune Infiltration and the Roles of HMOX1 in the Proliferation and Apoptosis were Investigated in Uveal Melanoma

Zhao,

Wang,

et al. 2024

Genes Genom

View full text Add to dashboard Cite

Background Uveal melanoma (UVM) is the most common primary ocular malignancy, with a wide range of symptoms and outcomes. The programmed cell death (PCD) plays an important role in tumor development, diagnosis, and prognosis. There is still no research on the relationship between PCD-related genes and UVM. A novel PCD-associated prognostic model is urgently needed to improve treatment strategies. Objective We aim to screen PCD-related prognostic signature and investigate its proliferation ability and apoptosis in UVM cells. Methods The clinical information and RNA-seq data of the UVM patients were collected from the TCGA cohort. All the patients were classified using consensus clustering by the selected PCD-related genes. After univariate Cox regression and PPI network analysis, the prognostic PCD-related genes were then submitted to the LASSO regression analysis to build a prognostic model. The level of immune infiltration of 8-PCD signature in high- and low-risk patients was analyzed using xCell. The prediction on chemotherapy and immunotherapy response in UVM patients was assessed by GDSC and TIDE algorithm. CCK-8, western blot and Annexin V-FITC/PI staining were used to explore the roles of HMOX1 in UVM cells. Results A total of 8-PCD signature was constructed and the risk score of the PCD signature was negatively correlated with the overall survival, indicating strong predictive ability and independent prognostic value. The risk score was positively correlated with CD8 Tcm, CD8 Tem and Th2 cells. Immune cells in high-risk group had poorer overall survival. The drug sensitivity demonstrated that cisplatin might impact the progression of UVM and better immunotherapy responsiveness in the high-risk group. Finally, Overespression HMOX1 (OE-HMOX1) decreased the cell viability and induced apoptosis in UVM cells. Recuse experiment results showed that ferrostatin-1 (fer-1) protected MP65 cells from apoptosis and necrosis caused by OE-HMOX1. Conclusion The PCD signature may have a significant role in the tumor microenvironment, clinicopathological characteristics, prognosis and drug sensitivity. More importantly, HMOX1 depletion greatly induced tumor cell growth and inhibited cell apoptosis and fer-1 protected UVM cells from apoptosis and necrosis induced by OE-HMOX1. This work provides a foundation for effective therapeutic strategy in tumour treatment.

show abstract

Methods for combination treatment of metastatic uveal melanoma

Kolomiets,

Ponomareva,

Posypina

et al. 2023

BRSMU

View full text Add to dashboard Cite

Uveal melanoma (UM) is a rare primary malignant tumor originating from uveal melanocytes (choroid (90%), ciliary body (6%), iris (4%)) of the eye. According to the aggregate data, the tumor incidence is 5.2 cases per 1 million population. In Russia this value varies between 6.23–8 cases per 1 million adult population across the regions. UM most often spreads to the liver (89–93%). The clinical case of using transarterial chemoembolization (carboplatin) in combination with immunotherapy (nivolumab + ipilimumab) in patients with metastatic liver disease from UM is provided. The disease control within 12 months has been achieved, which, in turn, demonstrates the possibility and efficacy of multidisciplinary approach.

show abstract

Minimally Invasive Treatment Options for Hepatic Uveal Melanoma Metastases

Cited by 3 publications

References 69 publications

From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma

From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma

Programmed Cell Death-Related Gene Signature Associated with Prognosis and Immune Infiltration and the Roles of HMOX1 in the Proliferation and Apoptosis were Investigated in Uveal Melanoma

Methods for combination treatment of metastatic uveal melanoma

Contact Info

Product

Resources

About